title: Reversing resistance of multidrug-resistant hepatic carcinoma cells with parthenolide.
abstract: OBJECTIVE
  To investigate the mechanism of reversing resistance of a hepatic carcinoma multidrug-resistant cell BEL-7402/5-FU with parthenolide (PTL).
  
  
  METHODS
  BEL-7402/5-FU cells were treated with different concentrations of PTL and/or 5-fluorouracil. The proliferation inhibition rates, NF-κB, P-glycoprotein, MRP, Bcl-2, WNT1 and p53 levels were determined.
  
  
  RESULTS
  The results showed that PTL did not only have proliferation inhibition influence on BEL-7402/5-FU in a concentration-dependent manner, but also significantly increased the proliferation inhibition role of 5-fluorouracil on BEL-7402/5-FU, to reverse the resistance of hepatic carcinoma-resistant cells. PTL could also inhibit the NF-κB activity and the expression of P-glycoprotein, MRP, Bcl-2 and WNT1, and increase the expression of p53.
  
  
  CONCLUSIONS
  Our research suggests that clinical administration of PTL may be useful for hepatic carcinoma patients.
authors.affiliation: Renal Department, China Medical University Affiliated Shengjing Hospital, Shenyang, Liaoning, China.
authors.forename: Dajun
authors.initials: D
authors.lastname: Liu
authors.forename: Ying
authors.initials: Y
authors.lastname: Liu
authors.forename: Minghua
authors.initials: M
authors.lastname: Liu
authors.forename: Limei
authors.initials: L
authors.lastname: Ran
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B / Q000378:metabolism; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005472:Fluorouracil / Q000494:pharmacology; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D016328:NF-kappa B / Q000037:antagonists & inhibitors; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D012717:Sesquiterpenes / Q000494:pharmacology*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D051155:Wnt1 Protein / Q000378:metabolism
chemical_list: D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000964:Antimetabolites, Antineoplastic; D016328:NF-kappa B; D019253:Proto-Oncogene Proteins c-bcl-2; D012717:Sesquiterpenes; D016159:Tumor Suppressor Protein p53; D051155:Wnt1 Protein; C002669:parthenolide; D005472:Fluorouracil